| 1 | A new kind of magnetic targeting induction heating drug carrier and its physical and biological properties显示文摘Nano-carbon and iron composite―carbon-coated iron nanoparticles (CCINs) produced by carbon arc method can be used as a new kind of magnetic targeting induction heating drug carrier for cancer therapy. The structure and morphology of CCINs are studied by X-ray diffraction (XRD) and transmission electron microscope (TEM). Mossbauer spectra of these nanoparticles show that they contain only iron and carbon, without ferric carbide and ferric oxide. CCINs can be used as the magnetic drug carrier, with the effect of targeting magnetic induction heating in its inner core and higher drug adsorption in its nano-carbon shell outside because of its high specific surface area. CCINs can absorb Epirubicin (EPI) of 160 μg/mg measured by an optical spectrometer. In acute toxicity experiment with mice, the median lethal dose (LD50) of EPI is 16.9 mg/kg, while that of EPI-CCINs mixture is 20.7 mg/kg and none of the mice died after pure CCINs medication. The results show that pure CCINs belong to non-toxic grade and EPI delivery in mixture with CCINs can reduce its acute toxicity in mice. The magnetic properties of CCINs and their magnetic induction heating are investigated. The iron nanoparticle in its inner core has better magnetism with a good effect on targeting magnetic induction heating. When the CCINs are mixed with physiological salt water and are injected uniformly in pig's liver, the temperature goes up to 48℃. While in the case that CCINs are filled in a certain section of pig's liver, the temperature goes up to 52℃. In both cases the temperature is high enough to kill the cancer cell. CCINs have potential applications in cancer therapy. | ZHANG HaiYan CHEN YiMing ZHENG Yun LAO XiangMing ZENG GuoXun PANG JinShan WU QiGuang LI JinQing | 2009 | Science China(Technological Sciences)2009，52，10： | 2 |
| 2 | An evaluation of safety and survival for patients with locally advanced pancreatic cancer treated with irreversible electroporation combined with chemotherapy:a retrospectively observational study显示文摘Objective:lreversible electroporation(IRE)is emerging as a new therapy for locally advanced pancreatic cancer(LAPC).We aimed to conduct survival and safety analyses in L APC patients after treatment with IRE combined with chemotherapy.Methods:A total of 64 patients with LAPC who had received IRE and chemotherapy were retrospectively collected from August 2015 to March 2019 at Sun Yat-sen University Cancer Center.Overall survival(OS)and progression-free survival(PFS)were evaluated using Kaplan-Meier method and compared by the log-rank test.A multivariate Cox regression model was used to determine the prognostic factors of survival.The perioperative complications of IRE were also evaluated.The study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center(approval No.C2021-003).Results:The median survival of all included patients were 24.63(95%confidence interval:21.78-27.49)for overall survival and 13.00(95%confidence inteval:8.81-17.19)months for progression-free survival,with 96.8%,51.9%,18.3%;and 52.3%,21.5%,7.9%as the 1-,2-and 3-year OS and PFS rates,respectively.Tumor size[OS,hazard ratio(HR)=1.768,P=0.048;PFS,HR=0.304,P=0.010],neoadjuvant chemotherapy(OS,HR=0338,P=0.030;PFS,HR=0.358,P=0.034),carbohydrate antigen 19-9 variation after IRE(OS,HR=19.320,P=0.003;PFS,HR=14.591,P=0.021)and tumor response after neoadjuvant chemotherapy(OS,HR-8.779,P=0.033;PFS,HR-5.562,P=0.008)were predictive factors of survival in patients with LAPC after IRE.Complications were observed in 20.3%of patients.Grade B pancreatic fistula was the most common complication.The complication rates of the late treatment group(6.1%)were significantly lower than those of the first 15 patients after IRE treatment(66.7%).The median length of hospital stay of late treatment group was 8.6days,which was also shorter than that of the early treatment group(10.0days).Conclusions:IRE combined with chemotherapy could improve survival of LAPC patients with acceptable complication rates.Therefore,it may be a suitable method for LAPC but should be validated in prospective randomized trials. | Chaobin He Jun Wang Yize Mao Xiangming Lao Shengping Li | 2022 | Journal of Pancreatology2022，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员